Long-term implications of medical therapy on benign prostatic hyperplasia end points

Urology

Volumn 51, Issue 4 SUPPL. A, 1998, Pages 50-57

  Nickel, J Curtis ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN;

ADULT; AGED; ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; TREATMENT OUTCOME; URINE FLOW RATE;

ACUTE DISEASE; HUMANS; INCIDENCE; MALE; PROSTATIC HYPERPLASIA; TIME FACTORS; URINARY RETENTION;

EID: 0031957387     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00056-9     Document Type: Conference Paper

References (38)

1. Oesterling JE. Drug therapy benign prostatic hyperplasia - medical and minimally invasive treatment options . N Engl J Med. 332:1995;99-109.
2. Boyarsky S, Jones G, Paulson DF, Prout GR Jr. A new look at bladder neck obstruction by the Food and Drug Administration regulators guidelines for investigation of benign prostatic hypertrophy . Trans Am Assoc Genitourin Surg. 68:1976;29-32.
3. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
4. Rhodes T, Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Lieber MM. Longitudinal measures of prostate volume in a community-based sample: 3.5 year follow-up in the Olmsted County study of health status and urinary symptoms among men (Abstr.). J Urol. 153:1995;301A.
5. Drach G, Layton T, Binard W. Male peak urinary flow rate relationship to voided volume and age . J Urol. 122:1979;210-214.
6. Girman CJ, Panser L, Chute CG, Oesterling JE, Barrett DM, Chen CC, Arrighi HM, Guess HA, Lieber MM. Natural history of prostatism urinary flow rates in a population-based study . J Urol. 150:1993;887-892.
7. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism a population-based survey of urinary symptoms . J Urol. 150:1993;85-89.
8. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. Natural history of prostatism: four-year change in urinary symptom frequency and bother (Abstr.). J Urol. 153:1995;300A.
9. Norman RW, Nickel JC, Fish D, Pickett SN. Prostate-related symptoms in Canadian men 50 years of age or older prevalence and relationships among symptoms . Br J Urol. 74:1994;542-550.
10. Barry MJ, Fowler FJ Jr, Bin L, Pitts JC III, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 157:1997;10-15.
11. Malone PR, Cook A, Edmondson R, Gill MW, Shearer RJ. Prostatectomy patients perception and long-term follow-up . Br J Urol. 61:1988;234-238.
12. Arrighi H, Metter E, Guess H, Fozard J. Natural history of benign prostatic hyperplasia and risk of prostatectomy The Baltimore Longitudinal Study of Aging . Urology. 38:(suppl):1991;4-8.
13. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate. 22:1993;291-299.
14. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
15. Lepor H. The role of alpha blockade in the treatment of BPH. Lepor H, Lawson RK. Prostatic Diseases. 1993;170-181 WB Saunders, Philadelphia.
16. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P. A randomized multicenter placebo controlled study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 148:1992;1467-1474.
17. Janknegt RA, and Chapple CR, for the Doxazosin Study groups: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia: analysis of 5 studies. Eur Urol 24: 319-326, 1993.
18. 1c-adrenoceptor antagonist a randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH) . Br J Urol. 76:1995;325-336.
19. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
20. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT Study) . Can Med Assoc J. 155:1996;1251-1259.
21. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study . Urology. 46:1995;631-637.
22. Marberger JM, Marshall VR, Navarrete RV, Schulman CC. Continuous improvement with finasteride in symptomatic benign prostatic hyperplasia (Abstr.). J Urol. 157:(suppl):1997;133A.
23. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;286-294.
24. Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover L, Vaughan D, Pappas F. Proscar five-year experience . Eur Urol. 28:1995;304-309.
25. Lepor H, for The Terazosin Research Group: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 45: 406-413, 1995.
26. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N. Doxazosin for benign prostatic hyperplasia long-term efficacy and safety in hypertensive and normotensive patients . J Urol. 57:1997;525-530.
27. Lepor H. Tamsulosin, long-term open-label, extension study to evaluate therapeutic response and safety (Abstr.). J Urol. 157:(suppl):1997;331A.
28. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
29. Brawer M, for the Terazosin Investigators Group: The impact on response to long-term terazosin treatment in patients with symptomatic benign prostate hyperplasia (BPH). (Abstr.) Eur Urol 30: 152, 1996.
30. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM. Natural history of prostatism relationship among symptoms, prostate volume and peak urinary flow rate . J Urol. 153:1996;1510-1515.
31. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism risk factors for acute urinary retention . J Urol. 158:1997;481-487.
32. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and the need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 49:1997;839-845.
33. Somers WJ, Mora MJ, Mason MF, Padley RJ. The natural history of benign prostatic hypertrophy incidence of urinary retention and significance of AUA Symptom Score . J Urol. 155:1996;586A.
34. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE, Padley RJ. The Hytrin community assessment trial study a one-year study of terazosin vs placebo in the treatment of men with symptomatic benign prostatic hyperplasia . Urology. 47:1996;159-168.
35. McConnell JD, Roehrborn CG. Patient selection and symptom evaluation. Chisholm GD. Handbook on Benign Prostatic Hyperplasia. 1994;33-51 Raven Press, New York.
36. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 17:1990;495-507.
37. Waldstreicher J, for the PLESS Study Group: The long-term effects of finasteride on BPH: Results of a four-year, placebo-controlled study (Abstr. 758). Br J Urol 80(suppl 2): 194, 1997.
38. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med. 338:1998;557-563.